Advancing CNS Innovation Through Global Collaboration
HSNOHbio welcomes strategic partnerships with biotechnology and pharmaceutical companies, academic research institutions, contract research organizations (CROs), and venture capital investors.
Our lead program, G3-01EG, is an AI-designed small-molecule candidate being developed to selectively modulate the GluA3 AMPA receptor.
We seek collaborations in medicinal chemistry, compound synthesis, receptor binding assays, electrophysiology, preclinical validation, and drug development.
Partnership Opportunities
Research and development collaborations
CRO partnerships and experimental validation
Strategic investment and venture financing
Technology licensing and co-development
Contact: contact@hsnohbio.com
Location: New York, USA